Accueil・Liste d'Actions・Viking Therapeutics Inc

Viking Therapeutics Inc

Fermé

SecteurSoins de santé

33.34 1.62

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.81

Max

Chiffres clés
By Trading Economics
Revenu	30M -128M
BPA	-1.1
Employés	65
EBITDA	30M -128M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+179.54% upside

Dividendes
By Acuity
Prochains Résultats	21 oct. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-245M 3.8B
Ouverture précédente	31.72
Clôture précédente	33.34

Sentiment de l'Actualité

By Acuity

50%

156 / 340 Classement par Healthcare

Viking Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 août 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4 août 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 août 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 juil. 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 juil. 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 juil. 2026, 23:21 UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 juil. 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 juil. 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25 juil. 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24 juil. 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23 juil. 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22 juil. 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Comparaison

Variation de prix

Viking Therapeutics Inc prévision

Objectif de Prix

By TipRanks

179.54% hausse

Prévisions sur 12 Mois

Moyen 92.08 USD 179.54%

Haut 114 USD

Bas 70 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

156 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.